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4 apoA-I +32 ) has been detected in circulating HDL, and is present at increased concentrations in subjects with a genotype associated with increased coronary artery disease (16) . Moreover, it was recently shown that the MetO content of apoA-I is elevated in human type 1 diabetes (17) , a disorder commonly associated with increased oxidative stress (18) .
The above findings suggest that oxidized forms of apoA-I containing 3-chlorotyrosine and/or MetO could be clinically relevant. However, testing this possibility is limited by current methods for oxidized apoA-I detection that require time-consuming HDL isolation and HPLC-or mass spectroscopy-based detection steps. We therefore sought to develop a simple method for the specific detection of apoA-I containing MetO. Here we describe a sensitive and specific ELISA that detects MetO-containing apoA-I in HDL and plasma.
MATERIAL AND METHODS

Materials
Cell culture media and reagents including DMEM, fetal bovine serum, and hybridoma-SFM were purchased from Invitrogen (Carlsbad, CA). EZ-Link Sulfo-NHS-LCBiotin was obtained from Pierce (IL, USA). 2,2'-Azobis(2-amidinopropane) dihydrochloride (AAPH) was purchased from Wako Pure Chemical Ind. (Osaka, Japan), and 3,3',5,5'-tetramethylbenzidine, potassium bromide, diethylene triamine pentaacetic acid, ascorbic acid, sydnonimine-1, H 2 O 2 , bovine serum albumin (BSA, fraction V), myoglobin, ferritin and fibrinogen were obtained from Sigma (MO, USA). Sodium hypochlorite (4% solution) was obtained from Septone (Hemmant, Australia), while phosphate buffered saline pH 7.4 (PBS, 10 mM) was prepared from tablets (Oxoid, Basingstoke, England). Trifluoroacetic acid (TFA) and HPLC-grade water were obtained from British Drug House (Poole, England).
Other HPLC grade solvents were obtained from Merck (Darmstadt, Germany). All other by guest, on www.jlr.org Downloaded from D8:00042R-JLR 5 reagents used were of analytical grade. Water was purified by a Milli-Q Ultrapure water system (Millipore, Sydney, Australia).
Isolation of HDL
Fresh blood (200 mL) from healthy and overnight fasted subjects (male, age 30-50 years) was collected into heparinized vacutainers, and plasma obtained by centrifugation at 1,430 x g for 20 min at 4°C. HDL was isolated from the plasma by sequential ultracentrifugation (19) . Briefly, the density of pooled plasma was adjusted to 1.24 g/mL with potassium bromide and the plasma then centrifuged for 3 h at 206,360 x g and 10°C (Beckman Optima L-90K, VTi50 rotor). The resulting HDL band was aspirated, added to a new quick seal tube and topped up with 0.9% saline of 1.24 g/mL density (adjusted with potassium bromide, 381.6 mg/mL), and then re-centrifuged overnight at 206,360 x g and 10°C. HDL (top band) was removed and dialyzed generously against PBS containing 0.1% EDTA and 0.01% chloramphenicol. The obtained HDL was used within 24 h.
Oxidation of HDL
Native HDL (1-1.5 mg protein/mL) was oxidized in 20 mM PBS containing 100 µM diethylene triamine pentaacetic acid under air and at 37°C by exposure to either the peroxyl radical generator AAPH (2 mM, 3 h) (7), H 2 O 2 (100 mM, 24 h), or HOCl (500 µM, 1 h). The reactions were terminated by addition of butylated hydroxytoluene (100 µM), catalase (200 nM), or methionine (2.5 mM), respectively. The reaction mixture (1 mL) was then passed through a gel filtration column (3 mL, NAP-10, GE Healthcare, Uppsala, Sweden) eluted with 1.5 mL of PBS. The oxidized HDL was analyzed within 24 h.
HPLC analysis of native and oxidized HDL
Freshly isolated HDL (0.06 mg protein) or differently oxidized HDL (1 mg protein) was subjected to a C18 column (250 x 4.6 mm, 5 µm, Vydac) with guard (5 µm, 4.6 ID, by guest, on www.jlr.org Downloaded from D8:00042R-JLR 6 Vydac) eluted at 50°C and 0.5 mL/min, with the eluant monitored at 214 nm. The instrument settings were modified slightly from the previously described method (16) . Briefly, after initial equilibration in 25% Solvent A (acetonitrile containing 0.1 vol % TFA) and 75% Solvent B (water containing 0.1 vol % TFA) for 10 min, the concentration of Solvent A was increased linearly to 45% over 5 min, then to 55% over 32 min, to 95% over 10 min, and finally to 100% in 1 min, after which Solvent A was decreased to 25% for column reequilibration. For the purpose of preparation of apolipoprotein standards, a semi-preparative RP C18 column (250 x 10 mm, 5 µm, Vydac, flow rate 2 mL/min) was used to allow injection of HDL and differently oxidized HDL (up to 5 mg protein).
Apolipoprotein standards
Appropriate protein fractions of HDL and oxidized HDL eluting from the HPLC column were collected on ice, dried under vacuum (AES1010 speedyvac system, Thermo Savant, USA) and reconstituted in PBS. The identity of non-oxidized apoA-I and different forms of oxidized apoA-I, containing MetO instead of methionine residues as the only modification(s), was confirmed by mass spectroscopy, as described previously (16, 20) .
Reconstituted native and oxidized forms of apoA-I and apoA-II were overlaid with argon and stored at -20°C for up to 12 months prior to use. Such storage did not change the nature of D8:00042R-JLR 7 approval from the local animal ethics committee. Briefly, six Balb/c mice were immunized three times, four weeks apart by both subcutaneous and intravenous injection of 10 µg HPLC-purified human apoA-I +32 in Freund's adjuvant. The strongest responding mice, as shown by serum Ig levels on an ELISA, were chosen for the fusion. Five days before the fusion and at least four weeks after the previous boost immunization, a final boost apoA-I +32 (10 µg in saline) was administered by intravenous injection. On the day of fusion, spleen cells taken from the immunized mice were added to NS-1 cells in serum-free DMEM and the fusion carried out using 50% polyethyleneglycol. Fused cells were plated in 96-well plates with rat thymocyte feeder cells. Seven to ten days after the fusion, hybridoma supernate was screened for antibodies with solid-phase ELISA using apoA-I +32 as the immunogen.
Hybridomas from high producing cell pools were subsequently cloned by limited dilution.
Three rounds of clonal isolation were performed to obtain stable cell lines producing Finally, the concentration of B-mAb was determined by absorbance at 280 nm. For competition assay, plates were coated with 100 µL goat anti-human apoA-I polyclonal antibody (Rockland, 1:10,000 dilution in PBS), incubated at 4°C overnight, washed and blocked, and 100 µL apoA-I +32 (400 ng/mL) then added. After incubation (37°C) and washing (0.1% Tween 20 in PBS), 100 µL B-mAb17 (see below) and the competing antibody were added, the plate incubated for 1 h at 37°C, followed by color development.
Development of ELISA
For detection of oxidized forms of lipid-free apoA-I, respective apolipoproteins were used at serial dilutions (0-500 ng/mL PBS containing 2% BSA), and the sensitivity of the ELISA compared to the HPLC assay. For detection of oxidized apoA-I associated with HDL, 100 µL of AAPH-oxidized HDL (0-15 µg protein/mL) was added either in PBS containing 2% BSA, or in 40% acetonitrile. Signals were compared to readings obtained with lipid-free apoA-I +32 , with the amount of apoA-I +32 contained in AAPH-oxidized HDL determined by HPLC. Where indicated, native HDL (0-15 µg/mL) or LDL (0-15 µg/mL) was used. To apply the ELISA to human plasma, plasma samples (10 µL) were filtered (0.22 µm), supplemented with 90 µL oxidized HDL (0-15 µg) and then applied to a hydrated SwellGel Blue column (SwellGel Blue albumin removal kit, Pierce). After 2 min incubation at RT, columns were centrifuged (12,000 x g, 1 min). The sample flow-through (100 µL)
was re-applied to the column, the column re-centrifuged, and the second sample flow-through (100 µL) collected. The column was then washed with 400 µL optimized buffer (25 mM Tris, 300 mM NaCl, pH 7.4), the wash flow-through (400 µL) collected and combined with the above second sample flow-through prior to ELISA.
SDS-PAGE
SDS-PAGE was performed using 10% bis-TRIS Nupage gels (Invitrogen) under reducing conditions. Samples loaded consisted of 1 µL of 10 x diluted plasma without and with an aliquot (15 µg protein) of the oxidized HDL loaded onto the SwellGel Blue, or 5 µL of the combined sample and wash flow-through prepared as described above. After electrophoresis, proteins were transferred to nitrocellulose membranes (Hybond ECL, Amersham Biosciences), and immunoblotted using polyclonal goat anti-human apoA-I (Rockland) antibody as the primary and anti-goat horseradish peroxidase (Sigma) as the secondary Ab.
Preparation of differently oxidized lipid-free apoA-I
Solutions of lipid-free apoA-I (5 µM) in 20 mM PBS containing 100 µM diethylene triamine pentaacetic acid were oxidized under air at 37°C in the presence of different 1e-or 2e-oxidants. Specifically, for the Fenton reaction, 2 h incubation with FeCl 3 (10 µM) plus For controls, incubations were carried out in the absence of the respective oxidant.
Differently oxidized forms of apoA-I were then subjected to ELISA (250 ng protein/mL) and, after gel filtration, to HPLC (5 µg protein).
Wild type apoA-I and mutants with one, two or three of the methionine residues replaced with leucine residues were expressed in E. coli as described (14, 21) . Individual substitution mutations within human apoA-I cDNA were introduced by primer-directed PCR mutagenesis or mega-primer PCR. All mutations were verified by dideoxy automated fluorescent sequencing of cDNA, and confirmed by MS analysis of the protein (13, 22) .
These mutants (5 µM) were then exposed to 20 mM phosphate buffer pH 7.4 containing 100 µM diethylene triamine pentaacetic acid without (control) and with H 2 O 2 (50 mM) at 37°C for 24 hours to convert the remaining methionine residue(s) to the corresponding MetO. The reaction was terminated by addition of 200 nM catalase (to scavenge remaining H 2 O 2 ) and 10 mM methionine (to inhibit further oxidation). The formation of MetO was confirmed by LC-ESI-MS/MS analysis of tryptic or Glu-C digests of oxidized apoA-I protein and the product yield of individual MetO residues was determined with reconstructed ion chromatograms of product and precursor peptides as described (14) . Wild type and mutant native and oxidized apoA-I were then shipped to Sydney for ELISA (500 ng protein/mL) and HPLC analyses (5 µg protein).
Preparation of oxidized, methionine residue-containing proteins
by guest, on www.jlr.org Downloaded from D8:00042R-JLR 11 Native HDL (1 mg/mL) or 1 mg/mL BSA, myoglobin, ferritin or fibrinogen were oxidized at 37°C in 20 mM PBS containing 100 µM diethylene triamine pentaacetic acid with either H 2 O 2 (100 mM) or HOCl (500 µM). Samples were incubated for 24 h (H 2 O 2 ) or 1h (HOCl) and oxidation terminated by addition of catalase (200 nM) or methionine (2.5 mM), respectively. Oxidized proteins were then subjected to ELISA.
Statistical analysis
Data are shown as mean ± SEM unless otherwise stated. Intra-and inter-assay reproducibility was determined in four independent analyses each in triplicate.
RESULTS
Native HDL isolated from freshly obtained human plasma contains apolipoproteins apoA-I and apoA-II as the major proteins, which can be separated by HPLC (Fig. 1A) .
AAPH-oxidized HDL contained oxidized forms of apoA-I and apoA-II, which exhibit shorter retention times compared to their respective native forms (Fig. 1B) . These oxidized forms of apoA-I were designated apoA-I +32 ( were the only modifications present in these oxidized forms of apoA-I, as verified by LC-MS/MS (16, 20) . Native apoA-II and its oxidized form (apoA-II +16 ) eluted as three distinct, albeit incompletely resolved species (Fig. 1B) , characterized recently (20) .
To develop an ELISA for MetO-containing apoA-I, we immunized 6 mice with HPLCpurified human apoA-I +32 (16) . Of the sera from these mice, two showed increased recognition of apoA-I +32 over apoA-I (Fig. 1C) . Fig. 2) , as did several commercial polyclonal anti-human apoA-I antibodies (i.e., 600−101−109 from Rockland, A95120H from Biodesign, and AB740 from Chemicon) (data not shown). In contrast, mAb010-A/11 (from Chemicon) and MOA-I bound mutually exclusive epitopes, as absorbance remained unchanged (Fig. 2) . Therefore, we used mAb010-A/11 for capture and B-MOA-I for secondary detection in all subsequent experiments.
We first tested the specificity of MOA-I for various HPLC-purified, oxidized forms of lipid-free apoA-I. As can be seen, MOA-I detected apoA-I +32 in a concentration-dependent manner and yielding a linear response (Fig. 3A) . There was no cross-reactivity with apoA-I and apoA-II (Fig. 3A) , and comparatively modest recognition of apoA-I +16 (MetO 112 or Met 86 ) (Fig. 3B) . Intra-and inter-assay variation for apoA-I +32 was 3.8 ± 2.7 and 6.3 ± 2.9%, respectively. The sensitivity of the ELISA for apoA-I +32 was nearly three orders of magnitude greater than that of the HPLC method, with detection limits of 3 ng/mL (Fig. 4A) and 1 µg/mL (Fig. 4B) , respectively.
We next applied the ELISA to lipid-free apoA-I oxidized in vitro by different radical (i.e., 1e-oxidants) or non-radical (2e-) oxidants. The results show that MOA-I recognized apoA-I oxidized with the 2e-oxidants HOCl, H 2 O 2 and peroxynitrite (derived from sydnonimine-1) (Fig. 5A) . These 2e-oxidants are well known to oxidize methionine residues in proteins to MetO. In the case of apoA-I, this results in formation of apoA-I +32 (7, 8) , as verified by HPLC for HOCl, H 2 O 2 and peroxynitrite (data not shown). In contrast, lipid-free apoA-I oxidized by 1e-oxidants (i.e., hydroxyl radical and metal ions) was poorly recognized by MOA-I (Fig. 5A) , and did not contain substantial amounts of apoA-I +32 or apoA-I +16 , as Table 1) , and the proteins then subjected to ELISA. As expected, H 2 O 2 -oxidized wild type apoA-I yielded a high signal compared to the corresponding non-oxidized apoA-I (Fig. 5B) . Compared with oxidized wild type apoA-I, oxidized single methionine to leucine substituted apoA-Is gave smaller signals, although they were still recognized to a greater extent than the corresponding non-oxidized counterparts, except for M148L apoA-I (Fig. 5B, upper panel) . Consistently smaller signals were recorded with the oxidized double mutants (M86L/M148L and M112L/M148L) and the oxidized triple mutant (Fig. 5B, lower panel). HPLC analyses of the respective wild type and mutant apoA-Is revealed that high ELISA reactivity was associated with substantially shorter retention time of the oxidized compared to the non-oxidized protein (data not shown). Finally, we assessed the specificity of MOA-I for MetO contained in apoA-I versus other proteins. For this we exposed lipid-free apoA-I, BSA, ferritin, myoglobin and fibrinogen to H 2 O 2 or HOCl to convert their methionine residues to MetO prior to ELISA.
As can be seen, of these proteins only oxidized apoA-I yielded positive ELISA readings (Fig.   5D ). Together, these results indicate that MOA-I recognizes MetO specifically in apoA-I, and that the extent of this recognition increases with increasing MetO content.
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In a second part of our studies, we examined the suitability of the ELISA to detect MetO-containing apoA-I in HDL and in plasma. For this we utilized AAPH-oxidized HDL.
As can be seen, the ability of MOA-I to detect such oxidized HDL was modest (Fig. 6A) .
However, sensitivity was enhanced substantially when acetonitrile was added to the oxidized HDL prior to its application to the ELISA (Fig. 6A) . We chose acetonitrile to 'delipidate'
MetO-containing apoA-I in HDL because of its proven efficacy for this purpose in the HPLC assay. Optimization experiments revealed that acetonitrile at 40% final concentration gave best results (data not shown). At this concentration, the ELISA response for 'delipidated'
apoA-I +32 contained in oxidized HDL was similar to that observed with lipid-free apoA-I +32 (Fig. 6B) . The slightly higher response seen with oxidized HDL was likely due to the presence of some apoA-I +16 in oxidized HDL but not purified, lipid-free apoA-I +32 .
Compared to AAPH-oxidized HDL, the ELISA did not detect native LDL, and reactivity with freshly isolated, native HDL was low (Fig. 6C) . Detection of AAPH-oxidized HDL was reproducible, with intra-and inter-assay variation of 4.1 ± 3.2 and 9.3 ± 4.6%, respectively (n = 4 separate experiments, each carried out in triplicate).
We next examined whether the ELISA was suitable to detect oxidized HDL other than AAPH-oxidized HDL. For this, we used HDL oxidized with H 2 O 2 or HOCl, i.e., 2e-oxidants that directly convert methionine in apoA-I to MetO. Both, H 2 O 2 -and HOCl-oxidized HDL were clearly recognized by MOA-I (Fig. 6D) . Interestingly, and in contrast to the situation with AAPH-oxidized HDL, delipidation with acetonitrile was not required to detect H 2 O 2 -and HOCl-oxidized HDL. Importantly, the ELISA did not detect LDL oxidized with either H 2 O 2 or HOCl (Fig. 6D) , indicating specificity of the assay for HDL.
We next applied the ELISA to freshly obtained human plasma samples. Initial experiments revealed high background readings in diluted and lipid-extracted plasma samples (data not shown), and albumin to be responsible for this (Fig. 7A) . Efficient (i.e., >95%)
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D8:00042R-JLR 15 removal of albumin was achieved using the SwellGel Blue Albumin Removal Kit. However, such removal was not specific for albumin, as it also removed ~50-60% of apoA-I (data not shown). Specificity for albumin removal, i.e., >80% removal of albumin with essentially 100% apoA-I retained, was achieved with the Swellgel Blue approach using plasma volumes <20 µL and 300 mM NaCl, 25 mM Tris, pH 7.4 as the washing buffer (Fig. 7B&C) . This method was then used to examine the ELISA response to plasma containing increasing amounts of AAPH-oxidized HDL. As can be seen, the ELISA response to plasma containing increasing amounts of oxidized HDL was linear (Fig. 7D) . Importantly, the extent of the response was comparable for isolated oxidized HDL (diamonds in Fig. 7D ) and oxidized HDL added to plasma (circles in Fig. 7D ). The intra-and inter-assay variation for oxidized HDL in plasma was 7.6 ± 3.6 and 13.3 ± 5.3%, respectively. Together, these results indicate the usefulness of the ELISA for the determination of MetO-containing, HDL-associated apoA-I in human plasma.
DISCUSSION
It has been proposed that oxidized HDL plays a major role in atherogenesis, yet most presently available methods to detect oxidized HDL are not readily applicable to large numbers of clinical samples because they are time consuming and require specialized and expensive equipment. The present work describes a simple and robust ELISA for the specific detection of MetO-containing apoA-I in HDL as a novel tool potentially useful for evaluating the relationship between oxidized HDL, atherosclerosis and coronary artery disease.
The ELISA described here is based on MOA-I, a monoclonal antibody that we raised apoA-I +32 but not native apoA-I (Fig. 3A) purified from oxidized and native human HDL by HPLC. Second, the experiments with recombinant human wild type and mutant apoA-Is ( Fig.   5) showed that methionine residues were required for MOA-I to recognize H 2 O 2 -oxidized apoA-I. In the absence of cysteine residues in apoA-I, H 2 O 2 selectively oxidizes methionine to MetO. Importantly, we used MS-based methods to unambiguously identify and confirm
MetO as the only modified chemical moiety in the different forms of oxidized apoA-Is used in these experiments. In addition to H 2 O 2 -oxidized apoA-I, MOA-I also recognized lipid-free apoA-I oxidized by other 2e-oxidants (HOCl and peroxynitrite), whereas the antibody was non-reactive towards apoA-I modified by 1e-oxidants (Fig. 5) . It is well established that 2e-oxidants, but not 1e-oxidants, effectively convert methionine residues into MetO (7, 8) .
Finally, specificity of MOA-I for MetO-containing apoA-I is indicated by the fact that the ELISA did not detect H 2 O 2 -or HOCl-treated, methionine-containing proteins other than apoA-I.
In contrast to isolated, lipid-free apoA-I, MOA-I recognized HDL oxidized by 2e-oxidants and 1e-oxidants, i.e., peroxyl radicals. This observation is explained readily by the fact that 1e-oxidants, like AAPH-derived peroxyl radicals, preferentially react with the lipoprotein's lipids. This causes lipid peroxidation with the resulting accumulation of hydroperoxides of phospholipids and cholesterylesters (23) that then oxidize apoA-I's methionine to MetO (7, 8, 24, 25) . The fact that our ELISA recognizes HDL oxidized by a range of different oxidants increases its likely applicability to biological samples, at least in the context of cardiovascular diseases. This is because various oxidants contribute to oxidative modifications taking place in the affected arterial wall during atherogenesis (1).
Thus, while "oxidized HDL" is not a chemically defined term, the presence of MetOcontaining apoA-I in such modified lipoproteins likely represents a feature of oxidative damage required for MOA-I recognition. 
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We raised MOA-I using apoA-I +32 as the immunogen because this specifically oxidized apoA-I is formed as a major and relatively stable oxidation product when HDL is exposed to radical oxidants in vitro (16) . Also, apoA-I +32 has physical properties clearly distinct from native, non-oxidized apoA-I that allows the two forms of the protein to be separated by HPLC (Fig. 1) , and that we hypothesized would generate antigen(s) suitable for the generation of mAbs. Indeed, sera from two of the six animals immunized with apoA-I +32
showed increased recognition of apoA-I +32 over apoA-I (Fig. 1C) . Perhaps more surprisingly, we noticed that most commercially available monoclonal and polyclonal anti-human apoA-I antibodies also preferentially recognized apoA-I +32 over native apoA-I (not shown). We We are aware of only two previously reported antibodies against oxidized apoA-I or HDL, i.e., mAb C311 raised against AAPH-oxidized apoA-I (27), and mAb 9F5-3a raised against HDL oxidized by CuSO 4 (28) . Both these mAbs likely recognize epitopes not directly related to MetO, as MetO is not a major product in apoA-I oxidized with AAPH (7), 
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and it is not responsible for cross-linked apoA-I that is recognized by mAb 9F5-3a (29) .
Irrespective, Nakajima and co-workers reported increased levels of 'oxidized HDL', defined by immunoreactivity with mAb 9F5-3a, in plasma from patients with coronary artery disease compared to healthy subjects and patients with non-insulin-dependent diabetes mellitus (29) .
It remains to be established how this finding relates to the presence of 'oxidized HDL' with MetO-containing apoA-I.
Our results with isolated mutants (Fig. 5) indicate that the extent of recognition by MOA-I is higher for apoA-I with all three methionine residues present as MetO than for apoA-I +32 , the immunogen used in the present study. Thus, rather than directly recognizing MetO, MOA-I appears to bind a conformational epitope of apoA-I that is generated as its three methionine residues become converted to MetO. This interpretation is consistent with the lack of ELISA response to methionine-containing proteins other than apoA-I, oxidized by Filtered and 1:10 diluted plasma (total volume 100 µL) before ("B") or after ("A") SwellGel
Blue column filtration was subjected to SDS-PAGE/Western as described in the Materials.
Representative Western blots are shown. C, Quantification of the Western data shown in B.
Results are expressed as the ratio of apoA-I before to after SwellGel Blue albumin removal process. D, ELISA detection of MetO-containing apoA-I in HDL and added to human plasma. Fresh plasma (10 µL) was spiked with increasing concentrations of AAPH-oxidized HDL (0−15 µg/mL) and then passed through SwellGel Blue column, washed with optimized buffer (300 mM NaCl, 25 mM Tris pH 7.4) and the combined flow-through and wash sample (total volume 100 µL) applied to ELISA as described in the Materials and Methods section.
For comparison, the response to AAPH-oxidized HDL added to plasma and passed through n/a n/a n/a n/a M86L/M112L/M148L M86L/M112L/M148Lox n/a n/a n/a n/a n/a n/a
Wild type and mutant forms of apoA-I were expressed, purified and then oxidized with reagent H 2 O 2 as described in Materials and Methods. Oxidized proteins were then analyzed by LC-ESI-MS/MS to verify the extent of oxidation of methionine residues to MetO. Yield of MetO (%) = peak area of product ion / sum (peak area of precursor ion + peak area of product ion) × 100. The data represent averages of two sets of independent analyses, with the variation between the respective two values <3%.
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